Mobile

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not a...

Update Il y a 4 ans
Reference: ISRCTN10059974

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy

Woman Man

  • | Country :
  • France
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Not provided at time of registration

Inclusion criteria

  • Localised breast cancer not amenable to breast conserving therapy

Links